Herpes zoster virus infection and rheumatic diseases: Current state of the problem
https://doi.org/10.14412/1996-7012-2016-3-69-76
Abstract
This review deals with infection caused by Herpes zoster (HZ) reactivation in rheumatic diseases (RD). The absolute majority of studies show that the incidence of HZ infection in RD is 2–10-fold higher than the population one. Patient age, gender, use of glucocorticoids, and duration and severity of the disease are identified as risk factors. Vaccination against HZ infection is sure to be important for patients with RD. Investigation of the efficacy and safety of a new adjuvant NZ/su vaccine in patients with RD is of interest today.
About the Authors
D. V. Bukhanova
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
References
1. Kaslow RA, Stanberry LR, LeDuc JW. Viral infection of humans: epidemiology and controls. 5th ed. New York: Springer Science Business Media; 2014. P. 971-96.
2. Chen N, Li Q, Zhang Y, et al. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007795. doi: 10.1002/14651858. CD007795.pub2.
3. U.S. Department of Health & Human Services, Shingles (Herpes Zoster). http://www.cdc.gov/shingles/index.html.
4. Pinchinat S, Cebrian-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013 Apr 10;13:170. doi: 10.1186/1471-2334-13-170.
5. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014 May 13;348:g2911. doi: 10.1136/bmj.g2911.
6. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and noninflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-5.
7. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patientswith rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007 Dec 15;57(8):1431-8.
8. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Mar;65(3):353-61. doi: 10.1002/acr.21812.
9. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009 May 15;48(10):1364-71. doi: 10.1086/598331.
10. Veetil BM, Myasoedova E, Matteson EL, et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a populationbased cohort study. Arthritis Care Res (Hoboken). 2013 Jun;65(6):854-61. doi: 10.1002/acr.21928.
11. Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558-61. doi: 10.3109/14397595.2014.984829.
12. Antonelli MA, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med. 1991;90(3):295-8.
13. Segan J, Staples MP, March L, et al. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor- α inhibitors. Intern Med J. 2015 Mar; 45(3):310- 8. doi: 10.1111/imj.12679.
14. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-44.
15. Pappas DA, Hooper MM, Kremer JM, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying anti- rheumatic drugs. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1671-8. doi: 10.1002/ acr.22628.
16. Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken). 2015 May;67(5):731-6. doi: 10.1002/acr.22470.
17. Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229-34.
18. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti- TNF therapy and the risk of herpes zoster. JAMA. 2013 Mar 6;309(9): 887-95. doi: 10.1001/jama.2013.1099.
19. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in treatment of rheumatoid arthritis: 5 years follow- up. Int J Rheum Dis. 2012;15(3):330-5.
20. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine. 2008 Oct;75(5):540-3. doi: 10.1016/j.jbspin.2007.10.011. Epub 2008 Jul 31.
21. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2014 Oct;66(10):2675-84. doi: 10.1002/art.38745.
22. Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Apr 25. pii: annrheumdis-2016-209131. doi: 10.1136/annrheumdis-2016-209131. [Epub ahead of print].
23. Borba EF, Ribeiro AC, Martin P, et al. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010 Apr;16(3):119-22. doi: 10.1097/RHU.0b013e3181d52ed7.
24. Manzi S, Kuller LH, Kutzer J, et al. Herpes zoster in systemic lupus erythematosus. J Rheumatol. 1995 Jul;22(7):1254-8.
25. Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol. 1994 Jan;21(1):84-6.
26. Moutsopoulos HM, Gallagher JD, Decker JL, et al. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 1978 Sep-Oct;21(7):798-802.
27. Hellman DB, Petri M, Whiting-O’Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore). 1987 Sep;66(5):341-8.
28. Moga I, Formiga F, Canet R, et al. Herpes-zoster virus infection in patients with systemic lupus erythematosus. Rev Clin Esp. 1995 Aug;195(8):530-3.
29. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013 Mar;22(3): 238-44. doi: 10.1177/0961203312470186.Epub 2012 Dec 20.
30. Chen HH, Chen YM, Chen TJ, et al. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66(7):1177-82.
31. Kang TY, Lee HS, Kim TH, et al. Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol Int. 2005 Mar;25(2):97-102. Epub 2003 Oct 31. doi: 10.1007/s00296-003-0403-3.
32. Skare TL, Dagostini JS, Zanardi PI, Nisihara RM. Infections and systemic lupus erythematosus. Einstein (Sao Paulo). 2016 Mar;14(1):47-51. doi: 10.1590/S1679- 45082016AO3490.
33. Chakravarty EF, Odell J, Rasmussen A, et al. Varicella Zoster Reactivation in Patients with Primary Sjö gren’s Syndrome and SLE [abstract]. Arthritis Rheumatol. 2015;67 (suppl 10).
34. Chen JY, Wang LK, Feng PH, et al. Risk of Shingles in Adults with Primary Sjö gren's Syndrome and Treatments: A Nationwide Population-Based Cohort Study. PLoS One. 2015 Aug 25;10(8):e0134930. doi: 10.1371/journal.pone.0134930. eCollection 2015.
35. Tsai SY, Lin CL, Wong YC, et al. Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis. Medicine (Baltimore). 2015 Jul; 94(28): e1138. doi: 10.1097/MD.0000000000001138.
36. Chen IJ, Tsai WP, Wu YJ, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology (Oxford). 2010 Dec;49(12):2429-37. doi: 10.1093/rheumatology/keq279. Epub 2010 Sep 13.
37. Fardet L, Rybojad M, Gain M, et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol. 2009 Aug; 145(8):889-93. doi: 10.1001/archdermatol.2009.152.
38. Zisman D, Bitterman H, Shalom G, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis. 2016 Jan;75(1):131-5. doi: 10.1136/annrheumdis- 2013- 205148.
39. Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. WGET Research Group. Am J Med. 2005 Dec;118(12):1416.
40. Foocharoen C, Siriphannon Y, Mahakkanukrauh A, et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis. 2012 Jun;15(3):277-83. doi: 10.1111/j.1756-185X.2012.01728.x
41. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858. doi: 10.1002/14651858. CD008858.pub2.
42. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84.
43. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59years. Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30.
44. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20.
45. Curtis JR, Turner A, Thomas C, et al. Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti- TNF Biologics [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10).
46. Yun H, Xie F, Baddley J, et al. Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10).
47. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein Especific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008 Jun;152(3):522-31. doi: 10.1111/j.1365-2249.2008.03633.x. Epub 2008 Mar 20.
48. Laing KJ, Russell RM, Dong L, et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis. 2015 Oct 1;212(7):1022-31. doi: 10.1093/infdis/jiv164. Epub 2015 Mar 17.
49. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.
50. Stadtmauer EA, Sullivan KM, Marty FM, et al. A Phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18.
51. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a Phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3.
Review
For citations:
Bukhanova DV, Belov BS. Herpes zoster virus infection and rheumatic diseases: Current state of the problem. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(3):69-76. (In Russ.) https://doi.org/10.14412/1996-7012-2016-3-69-76
Views:
1189
Email this article 